Key updates in therapies for relapsing-remitting multiple sclerosis (RRMS) from the 2025 American Academy of Neurology annual meeting are reported by Dr Patricia Coyle of Stony Brook University Hospital, Stony Brook, New York.
First, Dr Coyle highlights how baseline serum neurofilament light chain levels (sNfL) predict outcomes in RRMS. Analysis of new or enlarging T2 lesions revealed that individuals with higher baseline sNfL were at increased risk for breakthrough disease activity.
Next, she reviews a study that analyzed data from up to 7 years of ofatumumab therapy. Starting therapy on ofatumumab led to excellent efficacy that resulted in increased reductions in 3- and 6-month disability worsening and 6-month disease progression compared with switching from teriflunomide to ofatumumab.
Dr Coyle highlights final results from the DAYBREAK extension study indicating ozanimod’s positive effect on slowing brain atrophy, and she concludes by discussing oral BTK inhibitors and anti-CD40 ligand monoclonal antibodies as promising future therapies in RRMS.
